African trypanosomiasis historical perspective
|
African trypanosomiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
African trypanosomiasis historical perspective On the Web |
|
American Roentgen Ray Society Images of African trypanosomiasis historical perspective |
|
Risk calculators and risk factors for African trypanosomiasis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Pilar Almonacid
Overview
History of treatment for sleeping sickness
Suramin was introduced in 1920 to treat the first stage of the disease. By 1922, Suramin was generally combined with Tryparsamide (another pentavalent organo-arsenic drug) in the treatment of the second stage of the gambiense form. It was used during the grand epidemic in West and Central Africa in millions of people and was the mainstay of therapy until 1969.
Pentamidine, a highly effective drug for the first stage of the disease, has been used since 1939. During the fifties, it was widely used as a prophylactic agent in Western Africa, leading to a sharp decline in infection rates. At the time, it was thought that eradication of the disease was at hand.
The organo-arsenical melarsoprol (Arsobal) was developed in the 1940s, and is effective for patients with second stage sleeping sickness. However, 3 - 10% of those injected have reactive encephalopathy (convulsions, progressive coma, or psychotic reactions), and 10 - 70% die; it can cause brain damage in those that survive the encephalopathy. However, due to its effectiveness, melarsoprol is still used today. Resistance to melarsoprol is increasing, and combination therapy with nifurtimox is currently under research.
Eflornithine (difluoromethylornithine or DFMO), the most modern treatment, was developed in the 1970s by Albert Sjoerdsmanot and underwent clinical trials in the 1980s. The drug was approved by the United States Food and Drug Administration in 1990, but Aventis, the company responsible for its manufacture, halted production in 1999. In 2001, however, Aventis, in association with Médecins Sans Frontières and the World Health Organization, signed a long-term agreement to manufacture and donate the drug.
The genome of the parasite has been decoded and several proteins have been identified as potential targets for drug treatment. The decoded DNA also revealed the reason why generating a vaccine for this disease has been so difficult. T. brucei has over 800 genes that manufacture proteins that the disease mixes and matches to evade immune system detection.[1]
An international research team working in the Democratic Republic of the Congo, Southern Sudan and Angola involving Immtech International and University of North Carolina at Chapel Hill have completed a Phase IIb clinical trial and commenced a Phase III trial in 2005 testing the efficacy of the first oral treatment for Sleeping Sickness, known at this point as "DB289". [2] [3]
Recent findings indicate that the parasite is unable to survive in the bloodstream without its flagellum. This insight gives researchers a new angle with which to attack the parasite.[4]
A new treatment based on a truncated version of the apolipoprotein L-1 of high density lipoprotein and a nanobody has recently been found to work in mice, but has not been tested in humans.[5]
References
- ↑ Berriman M, Ghedin E, Hertz-Fowler C; et al. (2005). "The genome of the African trypanosome Trypanosoma brucei". Science. 309 (5733): 416–22. doi:10.1126/science.1112642. PMID 16020726.
- ↑ Williamson, David (August 25, 2005). "Compound might defeat African sleeping sickness, clinical trial beginning this month". University of North Carolina.
- ↑ Staff (September 15, 2005). "Clinical Trials Update". Genetic Engineering News. p. 5.
- ↑ "African Sleeping Sickness Breakthrough". Retrieved April 7. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ New Scientist, 25 Aug. 2007, pp. 35-7